Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies.

Sheng Fu,Sheldon E. Litwin,Ryan J. Tedford

Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies.

2021

Sheng Fu
Sheldon E. Litwin
Ryan J. Tedford

SGLT-2 inhibitors show promise for treatment of heart failure with preserved ejection fraction, but clinical data are nuanced. Appropriate endpoint selection will be key to deciphering their benefits.

Keywords:

Intensive care medicine
Selection (genetic algorithm)
Heart failure
MEDLINE
Heart failure with preserved ejection fraction
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations